Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 12, 2013, Pages 1554-1565

  Bitencourt, Claudia S ^a   Bessi, Valérie L ^b   Huynh, David N ^b   Ménard, Liliane ^b   Lefebvre, Julie S ^c   Lévesque, Tania ^c   Hamdan, Leila ^b   Sohouhenou, Fanny ^b   Faccioli, Lucia H ^a   Borgeat, Pierre ^c   Marleau, Sylvie ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c University Laval   (Canada)

Author keywords

Cell trafficking; Dermal inflammation; Ischaemia reperfusion; Leucotrienes; Lipid mediator; Myocardial infarction; Platelet activating factor; Polymorphonuclear neutrophil

Indexed keywords

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS;

AMELUBANT; AMIDINE; APAFANT; AZEPINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; PROPIONIC ACID DERIVATIVE; QUINOLINE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TRIAZOLE DERIVATIVE; VERLUKAST;

ANIMAL; ARTICLE; BIOASSAY; C57BL MOUSE; CELL MIGRATION; CONTRAST MEDIUM EXTRAVASATION; DERMATITIS; DERMIS; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; INFLAMMATION; ISCHAEMIA/REPERFUSION; LEUCOTRIENES; LIMB; LIPID MEDIATOR; MALE; METABOLISM; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PLATELET-ACTIVATING FACTOR; RABBIT; REPERFUSION INJURY; VASCULARIZATION;

CELL TRAFFICKING; DERMAL INFLAMMATION; ISCHAEMIA/REPERFUSION; LEUCOTRIENES; LIPID MEDIATOR; MYOCARDIAL INFARCTION; PLATELET-ACTIVATING FACTOR; POLYMORPHONUCLEAR NEUTROPHIL;

AMIDINES; ANIMALS; AZEPINES; BIOLOGICAL ASSAY; CARBAMATES; DERMIS; DISEASE MODELS, ANIMAL; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; EXTREMITIES; INFLAMMATION; LEUKOTRIENE B4; LEUKOTRIENES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL ISCHEMIA; NEUTROPHIL INFILTRATION; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; PROPIONATES; QUINOLINES; RABBITS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LEUKOTRIENE; REPERFUSION INJURY; TRIAZOLES;

EID: 84891144996     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12118     Document Type: Article

References (53)

1. Dorweiler B, Neufang A, Schmiedt W, et al. Limb trauma with arterial injury: long-term performance of venous interposition grafts. Thorac Cardiovasc Surg. 2003; 51: 67-72.
2. Ferreira R. The reduction of infarct size-forty years of research. Rev Port Cardiol. 2010; 29: 1037-53.
3. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med. 2011; 17: 1391-401.
4. Harkin DW, D'Sa AA, Yassin MM, et al. Reperfusion injury is greater with delayed restoration of venous outflow in concurrent arterial and venous limb injury. Br J Surg. 2000; 87: 734-41.
5. Korth U, Merkel G, Fernandez FF, et al. Tourniquet-induced changes of energy metabolism in human skeletal muscle monitored by microdialysis. Anesthesiology. 2000; 93: 1407-12.
6. Lambert IH, Pedersen SF, Poulsen KA. Activation of PLA2 isoforms by cell swelling and ischaemia/hypoxia. Acta Physiol. 2006; 187: 75-85.
7. Welbourn CR, Goldman G, Paterson IS, et al. Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br J Surg. 1991; 78: 651-5.
8. Wang WZ, Guo SZ, Tsai TM, et al. Platelet-activating factor contributes to postischemic vasospasm. J Surg Res. 2000; 89: 139-46.
9. Goldman G, Welbourn R, Paterson IS, et al. Ischemia-induced neutrophil activation and diapedesis is lipoxygenase dependent. Surgery. 1990; 107: 428-33.
10. Homer-Vanniasinkam S, Gough MJ. Role of lipid mediators in the pathogenesis of skeletal muscle infarction and oedema during reperfusion after ischaemia. Br J Surg. 1994; 81: 1500-3.
11. Klausner JM, Paterson IS, Goldman G, et al. Thromboxane A2 mediates increased pulmonary microvascular permeability following limb ischemia. Circ Res. 1989; 64: 1178-89.
12. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003; 69: 123-34.
13. Marleau S, Fruteau de Laclos B, Sanchez AB, et al. Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit. J Immunol. 1999; 163: 3349-458.
14. Hicks A, Monkarsh SP, Hoffman AF, et al. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs. 2007; 16: 1909-20.
15. Claesson HE, Haeggstrom J. Human endothelial cells stimulate leukotriene synthesis and convert granulocyte released leukotriene A4 into leukotrienes B4, C4, D4 and E4. Eur J Biochem. 1988; 173: 93-100.
16. Lehr HA, Guhlmann A, Nolte D, et al. Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster. J Clin Invest. 1991; 87: 2036-41.
17. Rovati GE, Capra V. Cysteinyl-leukotriene receptors and cellular signals. ScientificWorldJournal. 2007; 7: 1375-92.
18. Garcia MC, Fernandez-Gallardo S, Gijon MA, et al. Biosynthesis of platelet-activating factor (PAF) in human polymorphonuclear leucocytes. The role of lyso-PAF disposal and free arachidonic acid. Biochem J. 1990; 268: 91-8.
19. Whatley RE, Fennell DF, Kurrus JA, et al. Synthesis of platelet-activating factor by endothelial cells. The role of G proteins. J Biol Chem. 1990; 265: 15550-9.
20. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000; 190: 255-66.
21. 4 and platelet-activating factor in human neutrophils. Br J Pharmacol. 1994; 111: 852-60.
22. Sisson JH, Prescott SM, McIntyre TM, et al. Production of platelet-activating factor by stimulated human polymorphonuclear leukocytes. Correlation of synthesis with release, functional events, and leukotriene B4 metabolism. J Immunol. 1987; 138: 3918-26.
23. Chakrabarty S, Fluck DS, Flores NA, et al. Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits. Br J Pharmacol. 1992; 107: 705-9.
24. Van Putte BP, Kesecioglu J, Hendriks JM, et al. Cellular infiltrates and injury evaluation in a rat model of warm pulmonary ischemia-reperfusion. Crit Care. 2005; 9: R1-8.
25. Tremblay P-B, Macari DMT, Martel D, et al. Hypoxemia modifies circulating and exudate neutrophil number and functional responses in carrageenin-induced pleurisy in the rat. J Leukoc Biol. 2000; 67: 785-92.
26. Chouinard F, Lefebvre JS, Navarro P, et al. The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B4 biosynthesis. J Immunol. 2011; 186: 3188-96.
27. Bessi VL, Labbe SM, Huynh DN, et al. EP 80317, a selective CD36 ligand, shows cardioprotective effects against post-ischaemic myocardial damage in mice. Cardiovasc Res. 2012; 96: 99-108.
28. Nagy L, Lee TH, Goetzl EJ, et al. Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products. Clin Exp Immunol. 1982; 47: 541-7.
29. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009; 49: 123-50.
30. Robinson DR. Lipid mediators of inflammation. Rheum Dis Clin North Am. 1987; 13: 385-405.
31. Borgeat P, Naccache PH. Biosynthesis and biological activity of leukotriene B4. Clin Biochem. 1990; 23: 459-68.
32. Jancar S, Braquet P, Sirois P. Interactions of arachidonic acid metabolites and platelet activating factor and mechanism of action in hypersensitivity reactions. Braz J Med Biol Res. 1987; 20: 487-94.
33. Moilanen E, Kirkkola AL, Kankaanranta H, et al. Interactions between synthesis of platelet-activating factor and leukotriene B4 in isolated human polymorphonuclear leukocytes. Inflammation. 1993; 17: 705-14.
34. Namura Y, Shio H, Kimura J. LTC4/LTB4 alterations in rat forebrain ischemia and reperfusion and effects of AA-861, CV-3988. Acta Neurochir Suppl. 1994; 60: 296-9.
35. 4 and platelet-activating factor in polymorphonuclear leukocyte recruitment to dermal inflammatory sites in rats. Immunology. 2007; 124: 295-303.
36. 4 synthesis and diapedesis. Surgery. 1992; 111: 287-93.
37. 4. J Immunol. 1990; 145: 1906-11.
38. Goldman G, Welbourn R, Klausner JM, et al. Mast cells and leukotrienes mediate neutrophil sequestration and lung edema after remote ischemia in rodents. Surgery. 1992; 112: 578-86.
39. Klausner JM, Paterson IS, Kobzik L, et al. Leukotrienes but not complement mediate limb ischemia-induced lung injury. Ann Surg. 1989; 209: 462-70.
40. Kurose I, Argenbright LW, Wolf R, et al. Ischemia/reperfusion-induced microvascular dysfunction: role of oxidants and lipid mediators. Am J Physiol. 1997; 272: H2976-82.
41. Kubes P, Ibbotson G, Russell J, et al. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol. 1990; 259: G300-5.
42. Salas A, Panes J, Elizalde JI, et al. Reperfusion-induced oxidative stress in diabetes: cellular and enzymatic sources. J Leukoc Biol. 1999; 66: 59-66.
43. Bozza PT, Silva PM, Castro-Faria-Neto HC, et al. Increase in the rat blood leukocyte counts induced by PAF-acether is suppressed by general anesthesia. J Leukoc Biol. 1992; 51: 146-50.
44. 4 antagonist. J Pharmacol Exp Ther. 2001; 297: 458-66.
45. Rubin BB, Romaschin A, Walker PM, et al. Mechanisms of postischemic injury in skeletal muscle: intervention strategies. J Appl Physiol. 1996; 80: 369-87.
46. Camussi G, Aglietta M, Coda R, et al. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology. 1981; 42: 191-9.
47. McDonald PP, Pouliot M, Borgeat P, et al. Induction by chemokines of lipid mediator synthesis in granulocyte-macrophage colony-stimulating factor-treated human neutrophils. J Immunol. 1993; 151: 6399-409.
48. Shindo K, Koide K, Fukumura M. Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor. Thorax. 1997; 52: 1024-9.
49. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med. 2011; 236: 390-401.
50. Yano T, Fujioka D, Saito Y, et al. Group V secretory phospholipase A2 plays a pathogenic role in myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2011; 90: 335-43.
51. Matsuno K, Iwata K, Matsumoto M, et al. NOX1/NADPH oxidase is involved in endotoxin-induced cardiomyocyte apoptosis. Free Radic Biol Med. 2012; 53: 1718-28.
52. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007; 87: 245-313.
53. Stangl V, Baumann G, Stangl K, et al. Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc Res. 2002; 53: 12-30.